A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections

Pfizer

Status and phase: Completed; Phase 4

Conditions: Candidiasis; Aspergillosis; Cryptococcosis

Treatments: Drug: Voriconazole

Study type: Interventional

Funder types: Industry

Identifiers

NCT00647907

A1501018

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of Vfend for the treatment of fungal infections

Enrollment: 7 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Systemic or invasive fungal infection
• Infection caused by organism for which there is no current treatment or infection with evidence of failure and/or intolerance to treatment with approved antifungal agents

Exclusion criteria

• Liver function test abnormalities
• Renal disease
• Fungal infections not considered to be invasive or systemic

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

A

Experimental group

Treatment:

Drug: Voriconazole